Related Experiment Video

Updated: Jun 18, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Hepatitis B therapies and antiviral resistance detection and management

Giselle Holness1, Damaris C Carriero, Douglas T Dieterich

  • 1Department of Medicine, Director of Outpatient Hepatology, Division of Liver Diseases, Mount Sinai School of Medicine, Annenberg 21-42, New York, NY 10029, USA.

Expert Review of Gastroenterology & Hepatology
|November 26, 2009
PubMed

Insights

Hepatitis B virus (HBV) infection requires effective management to prevent serious liver disease. Early detection of antiviral resistance is crucial for optimizing treatment and improving patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection is a significant global health concern.
  • Chronic HBV can lead to severe liver conditions like cirrhosis and hepatocellular carcinoma.
  • Current treatments face challenges due to antiviral drug resistance, impacting long-term efficacy.

Purpose of the Study:

  • To highlight the importance of durable viral suppression in reducing HBV-related complications.
  • To emphasize the clinical challenge posed by antiviral resistance in chronic HBV management.
  • To underscore the necessity of early resistance detection for optimizing patient care.

Main Methods:

  • Review of current therapeutic strategies for chronic HBV infection.
  • Analysis of the impact of antiviral resistance on clinical outcomes.
  • Discussion of monitoring for therapeutic efficacy and resistance.

Main Results:

  • Durable viral suppression is linked to a lower risk of hepatocellular carcinoma and disease progression.
  • Antiviral resistance can lead to suboptimal clinical outcomes.
  • Early detection of resistance is critical for mitigating liver-related morbidity and mortality.

Conclusions:

  • First-line therapy with potent antiviral agents is recommended to minimize resistance risk.
  • Continuous monitoring of therapeutic efficacy and resistance is essential for effective chronic HBV management.
  • Optimizing treatment strategies is key to improving long-term outcomes for patients with HBV.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.